Method: Thirty-five male patients (ranging from 0.7-43.5y at the first MRI) with PLP1-related disorder were prospectively followed over 7 years. Patients were classified according to best motor function acquired before 5 years (MDS) into five categories (from PMD0 without motor acquisition to PMD4 with autonomous walking). We determined myelination and atrophy scores and measured corpus callosum area, volume of cerebellum, white matter and grey matter on 63 MRI.
INTRODUCTION
Pelizaeus-Merzbacher disease (PMD; OMIM 312080) and spastic paraplegia type 2 (SPG2; OMIM 312920) are prototypic inherited defects of central nervous system (CNS) myelin formation. This X-linked form of hypomyelinating leukodystrophy (HLD1, OMIM 312080) is caused by mutations of the proteolipid protein 1 gene (PLP1), which encodes the two major myelin proteins of the CNS, PLP and its spliced isoform DM20 in oligodendrocytes. The clinical findings associated with PLP1 mutations span a wide-spectrum continuum extending from severe congenital PMD forms to relatively mild late-onset SPG2 leading to the concept of PLP1-related disorders. 1 PMD in males is characterized by early (<6mo) impairment of psychomotor development. In the first years of active myelination, hypotonia is associated with neurological signs gradually modifying as the CNS matures (nystagmus, choreoathetotic movements, ataxia). The large majority of patients improve during childhood. We classify them according to the best motor function achieved between the ages of 2 years and 5 years (motor developmental score, MDS)
to demonstrate a genotype-phenotype correlation. 1 PMD1 (head control) and PMD2 (sitting position) are the most common forms and are usually associated with PLP1 duplications. Missense mutations are rare but usually cause the most severe forms without motor acquisitions and dystonia (PMD0 form, also named 'congenital' forms). PLP1 loss-of-function (null mutations and large deletions) leads to the mildest PMD3/PMD4 (or SPG2) forms with acquisition of walking capacities with/ without aid. Cognitive and behavioural development is also better preserved in mild forms.
The defect in CNS myelin formation is demonstrated by both dramatic and extensive abnormalities of multimodal evoked potentials in the CNS and a diffuse hypomyelinated pattern of the supratentorial white matter on magnetic resonance imaging (MRI).2 This 'hypomyelinated' pattern is characterized by a diffuse hypersignal of the white matter on T2-weighted and fluid-attenuated inversion recovery (FLAIR) sequences contrasting with a normal hypersignal or isosignal on T1-weighted sequences in comparison with grey matter. Clinical severity appears to correlate with degree of hypomyelination, and slow progression of myelination has been reported in the youngest patients.3-6 In parallel, local improvement of myelination was reported on MRIs of two out of four children classified with severe PMD after intra-cerebral grafting of neural stem cells, particularly at injection points.7
Progressive spastic paraplegia with pyramidal tract signs is subsequently observed in patients with both PMD and SPG2, leading to severe quadriplegia, amyotrophia, and optic atrophia at the end of the second-fourth decade and accompanied by the development of corticosubcortical atrophy on MRI and late cognitive decline.8 A recent large series of 50 males with PMD/SPG2 and 11 heterozygous females found a correlation between clinical severity and white matter atrophy of the whole brain and corpus callosum.9
However, there is still a dearth of MRI data on the natural time-course of PMD/SPG2. To address this gap, we set out to identify pertinent MRI biomarkers of disease evolution, through a prospective analysis of clinical exams and MRIs of 35 PLP1-mutated males with variable forms of PMD/SPG2, followed over 7 years.
METHOD Patients
Thirty-five males from 32 families with PLP1 mutations were enrolled from January 2002 to December 2009 for prospective follow-up. MDS was determined according to the best motor development observed between 2 years and 5 years, adapted from Cailloux et al. and Inoue, as: no motor acquisition (PMD0), only head control (PMD1), sitting (PMD2), walking with aid (PMD3), or autonomous walking (PMD4).1,10 Clinical follow-up was carried out by an experienced neuropaediatrician (OB-T) at each visit to our medical centre . All patients had at least one MRI (named MRI-1), and 17 patients had repeat MRIs (nine patients twice, five patients three times, and three patients four times) at a minimal interval of 1 year using the same MRI protocol at the same medical centre.
MRI data, image processing, and biomarkers
Images were acquired on a 1.5-Tesla Siemens MR scanner, as follows: axial, sagittal, and coronal slices; T1-weighted, T2-weighted, and FLAIR sequences (Fig. 1) . Anonymized series were co-registered and aligned with the anterior commissure-posterior commissure (ACPC) line (Iplan 3.0; Brainlab, Feldkirchen, Germany). Biomarkers explored across MRI data were atrophy and myelination scores, quantitative evaluation of corpus callosum area, volumes of cerebellum and white matter/grey matter compartments.
Atrophy and myelination scores: Myelination score (Table I) (Table I) is a semiquantitative score obtained on classical MRI interpretation by radiologists. To limit subjectivity in interpretation, the atrophy scores were determined in a blind way by two neuropaediatricians (CS and DT).
CNS segmentation, surface and volume measurements: These were performed using Iplan 3.0 on FLAIR slices as white matter-grey matter signal contrast was visually maximal. Corpus callosum and cerebellum segmentation was determined manually (Fig. 1) . Total intracranial volume (TIV) was determined instead of strict brain volume to take into account the brain growth in young patients and the predictable white as well as grey matter atrophy. TIV, white matter and grey matter compartments were determined and extracted automatically (Statistical Parametric Mapping 8, Wellcome Trust Centre for Neuroimaging, London, UK; Matlab 7.0, Mathworks, Sherborn, MA, USA). Grey matter and white matter maps (dicomizer AVIZO software, Visualization Sciences Group, FEI, US) were co-registered with ACPC-aligned MRI series. Corpus callosum area/TIV ratio, cerebellum volume/TIV ratio, white matter compartment/ TIV ratio and grey matter compartment/TIV ratio were calculated, to account for brain growth over time.
Statistical analysis
Statistical analysis was performed using Stata 13 (StataCorp, College Station, TX, USA). The tests were twosided, with a type-I error set at a=0.05. Quantitative data, expressed as mean and standard deviation or median and interquartile range according to statistical distribution, were compared between independent groups (PMD0-1, PMD2, and PMD3-4) using a KruskalWallis test followed by the appropriate post-hoc Dunn's test. An ANCOVA (analysis of covariance) was performed with age as the adjustment covariate. The assumption of the normality of residuals was also studied using the Shapiro-Wilk test. Our data not exhibiting normal distributions, a log-transformation was proposed to achieve normality of several variables and to allow the correct use of these analyses. As proposed by some statisticians, we chose to report all the individual p-values without doing any mathematical correc tion for distinct tests comparing groups.11 A particular focus was given to the magnitude of improvement and to the clinical relevance. 12 A longitudinal descriptive survey was led over a maximum of 7 years according to availability of MRI and biomarker data. 
Figure 1: Magnetic resonance imaging of patients with Pelizaeus-Merzbaher disease (PMD)/spastic paraplegia type 2 (SPG2); severe (PMD0; top row), intermediate (PMD2; intermediate row), and mild (PMD4; bottom row) forms. T1-weighted (a-c), T2-weighted (d-f), and fluid-attenuated inversion recovery (FLAIR) (g-i) axial slices, anterior commissureposterior commissure aligned, showing different degrees of hypomyelination according to motor development score. Corpus callosum manual segmentation on midline FLAIR (j-k) and T1-weighted (l) sagittal slices. Manual segmentation of cerebel lum on FLAIR axial slices (mo) through the middle cerebellar peduncle.

RESULTS
Table II summarizes patient MDS, genotype, and age at MRI acquisition. The population consisted of 19 duplicated patients and 16 patients with point mutation (Table II) . In total, we had 63 structural MRI available in 35 patients. Mean age at MRI-1 was 11.77.8 years (median 10.9y; range 0.7-43.5y). Table III gives mean and median ages in each group.
Myelination and atrophy scores
Myelination (on 62 MRIs) and atrophy scores (on 63 MRIs) were calculated from 35 patients.
The results of 35 MRI-1 were analyzed according to MDS using three groups PMD0-1, PMD2, and PMD3-4. There was no evidence of a difference in mean gross total myelination scores between the three groups, whereas the mean atrophy scores were more severe in ( a )
patients with PMD0-1 than in patients with PMD2 and PMD3-4 (PMD2, p=0.033; PMD3-4, p=0.040) (Table III) .
CNS, central nervous system; FLAIR, fluid-attenuated inversion recovery.
Analysis led on the subgroup of 17 patients who had successive MRIs revealed that atrophy scores increased over time in 82% of patients (14/17) (Fig. 2a) . Progressive atrophy was never observed before 5 years and was only present between 5 years and 7 years in two patients with PMD2 and one patient with PMD3. For the remaining patients, atrophy increased by 8.72% between 10 years and 20 years. In contrast, total myelination score clearly improved for 7/17 patients after the expected age of 2 years of complete myelination in normal children (Fig. 2b) . This increase was observed in the four patients with PMD2 and one patient with PMD3 analysed between 3 years and 7 years, but also for two patients (one PMD2 and one PMD3) between 7 years and 12 years. In the 10 remaining patients analysed after 7 years, myelination score remained stable except in one patient with PMD3 whose myelination score decreased during adolescence over a period of 6.5 years. Inter-individual variability was particularly visible in the PMD3-4 group (10 patients). We then considered the myelination score of the 10 individual white matter regions determined at MRI-1 in the different groups of patients. After adjusting for age, there was evidence that the mean myelination differed in only three regions. The frontal white matter (p=0.029) and anterior limb of the internal capsule (p=0.045) appeared less achieved in patients with PMD0-1 than patients with PMD3-4. Myelination of arcuate fibres (U fibres) was less achieved in patients with PMD0-1 (p=0.046) and PMD2 (p=0.045) than in patients with PMD3-4 (Table III) despite very poor U-fibre myelination scores in all groups. Interindividual variability in the regional myelination scores was particularly visible in the PMD3-4 group.
These results showed that in PLP1-related disorders, the MDS that we had previously used to demonstrate a genotype-phenotype correlation is strongly correlated with the MRI atrophy score used here. Myelination scores for frontal white matter and to a lesser extent the anterior limb of the internal capsule and U-fibres partially segregated the different severity groups.
Follow-up MRIs performed in 50% of our 35 patients demonstrated that myelination scores can improve actively between 3 years and 7 years and more rarely and to a lesser extent between 7 years and at least 12 years. During adolescence, myelination scores remain stable whereas atrophy scores clearly increase. We then quantified different white matter and grey matter structures to better assess this atrophic process.
Quantification of white matter and grey matter structures
We first quantified the area/volume ratios of two structures known to change during the active phase of myelin development: the corpus callosum, a pure white matter structure, and the cerebellum including white matter and grey matter (Fig. 1) . Considering the 35 MRI-1, we found that mean corpus callosum area/TIV ratio was statistically smaller in patients with PMD0-1 than in patients with PMD3-4 after adjustment for age (p=0.017; Table III ). However, both corpus callosum area/TIV ratio and cerebellum volume/TIV ratio decreased in 88% (n=15) and 76% (n=13), respectively, of the 17 patients that underwent successive MRI (Fig. 2c, d ).
Automated segmentation of white matter and grey matter on FLAIR sequences was effective for 27 MRI in 22 patients, including all groups of patients. There was no evidence of a difference in mean white matter and grey matter compartments between the different severity groups (Table III) . The grey matter compartment was usually twice as large as the white matter compartment. Two successive MRIs were interpretable in 5/22 analyzable patients. White matter and grey matter compartments remained stable over time except in two patients (one patient with PMD0 and one patient with PMD2) who underwent two successive MRI at adolescence, in whom white matter compartment/TIV ratio decreased.
These results suggest that in PLP1-mutated patients, corpus callosum area, but not its myelination level, is correlated with severity of impairment of motor milestones. Interestingly, cerebellum atrophy tends to occur over time in parallel with the corpus callosum atrophy, whereas the white matter compartment, despite its severe defect, tends to remain stable compared to the grey matter compartment, at least until adolescence. Sample size for grey matter and white matter evaluation Several patients are represented with empty symbols for visibility.
DISCUSSION
We analyzed cerebral MRIs performed at the same medical centre at a mean age of 12 years on a large cohort of PLP1-mutated male patients. The 35 patients included were representative of the broad clinical spectrum of severity usually described in the PMD/SPG2 phenotype. We used MDS that we had previously demonstrated to correlate to the genotype.1 MRI follow-up was possible in half of them, with 45 successive MRIs.
Our results show that MDS is more correlated to gross atrophy score than to gross myelination score. Looking at the frontal and anterior capsule, atrophy score seems to increase over time, which is consistent with results from a small series of patients with PMD,13,14 as well as a recent large series made up of male patients with PMD and pauci-symptomatic heterozygous females. 9 We found that atrophy in patients with PMD0-1 affects the corpus callosum, a pure white matter myelinated anatomic neuron body-free structure. This is in agreement with Laukka et al., suggesting a link between clinical severity and abnormal corpus callosum development. 9 We also found intra-individual change in atrophy over time, which would make the corpus callosum a potentially good morphological marker both for motor development and for disease progression with age. Corpus callosum atrophy of the most severe patients is also suggestive of global white matter loss in patients with PMD/SPG2.9 However, we were unable to find a correlation between MDS and white matter fraction despite a segmentation of 43% of the MRI, including all groups of patients. This might be because of the sample size. FLAIR sequences on MRI were well contrasted in all patients. The difficulties to segment white matter using SPM were more related to the quality of the FLAIR sequences during the MRI acquisition, particularly because of artefact movements of the head in link with patients' ataxia. Laukka et al.9 also struggled with automated segmentation in patients with PMD and so had to perform meticulous manual segmentation of the white matter, which might be particularly impracticable in routine.
Another hypothesis would be that proportions of white matter and grey matter compartments The absence of correlation between cerebellum volume and developmental score in our series argues against the cerebellum as a biomarker for motor development. However, cerebellum atrophy has been reported in severe PMD. 16 In addition, neuronal loss affecting particularly thalamic, hippocampal, and cerebellar neurons (Purkinje cells and neurons of the dentate nuclei) was reported on brain examination in different forms of PMD/SPG2, suggesting that cerebellum atrophy would be caused not only by white matter injury but also by grey matter loss. 15 Nevertheless, we found that cerebellum atrophy could increase over time. Interestingly, cerebellum volume decreased not only in an inter-individual manner from 5 years old but also in an intra-individual manner on the MRI follow-up. A recent study in children with typical development reported that cerebellum volume increases until the beginning of adolescence and then tends to decrease slightly thereafter. 22 These results point to cerebellum volume as a good marker for progressive grey matter and white matter injury with age in PMD/SPG2.
We failed to find a relationship between developmental score and global hypomyelination at the first MRI with adjustment to age, even though hypomyelination is the main neuropathological feature in PMD 15 and orientates the diagnosis on cerebral MRI. 2 This lack of relationship may be because of lack of power in our study, but either way, this putative link remains controversial. [4] [5] [6] Nevertheless, hypomyelination of frontal white matter, anterior limb of the internal capsule, and arcuate fibres was correlated to MDS, showing that the most anterior and late-myelinated regions are more affected in PMD/SPG2. Furthermore, intraindividual MRI follow-up revealed slight myelination progression until 12 years in five patients with classical and mild PMD, whereas no progression was observed in older patients. To confirm myelination progression in the earliest MRIs, we also analysed MRIs performed before (n=10 patients) and later than (n=7 patients) our study in patients including all severity scores (Fig. S1 ). We again found a slow progression of myelination until 12 years even in the most severe patients, whereas there was no global change in myelination in older patients. These findings are in agreement with MRI data already reported in young patients with classical and mild PMD. 6 This spontaneous progression of myelination during the first years of life might be of utmost importance for future therapeutic trials. For instance, the interpretation of patchy progression of brain myelination in young patients with PMD after local injections of neural stem cells warrants extreme caution. 7 In conclusion, this study highlights that not just hypomyelination but also brain atrophy are major features on MRI in PMD/SPG2. Myelination progression may be informative during the early years of life, but motor development score was more correlated to markers of atrophy.
Corpus callosum and cerebellum volumes may be good intra-individual markers of disease progression with age.
These findings could well be important for PMD/SPG2 patient follow-up in future therapeutic trials.
